Synuca Therapeutics

Synuca Therapeutics combines decades of groundbreaking research in P-type ATPases and neuroscience from Aarhus University to propose a novel disease-modifying treatment for patients suffering from Parkinson's Disease and associated disorders. By targeting the SERCA calcium transporter, our first-in-class small molecules salvage the root disease cause by repairing the neuronal calcium imbalances caused by pathological α-Synuclein brain species.